Oct 19 (Reuters) – Hong Kong-listed Metis TechBio said on Monday it has entered into a collaboration agreement with Eli Lilly worth up to $1.1 billion to research and develop tissue-specific drug
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Liverpool urge patience with Szoboszlai injury, Frimpong suffers new setback
VIDEO SHOWS: PRESS CONFERENCE WITH LIVERPOOL MANAGER ANDONI IRAOLA COMPLETE SHOTLIST AND SCRIPT TO FOLLOW…
BRIEF-Schneider Electric Launches EUR 6.0 Bln Capital Increase To Partly Finance PTC Acquisition
Oct 19 (Reuters) - Schneider Electric SE: * LAUNCHES EUR 6.0 BILLION CAPITAL INCREASE TO…
Woman tells UK court that comedian Russell Brand raped her
By Michael Holden LONDON, Oct 19 (Reuters) - A woman told police that British actor…
